tailieunhanh - Báo cáo hóa học: " Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients | Chim Journal of Translational Medicine 2010 8 124 http content 8 1 124 JOURNAL OF TRANSLATIONAL MEDICINE RESEARCH Open Access Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib thalidomide dexamethasone in transplant eligible patients Chor Sang Chim Abstract Background Bortezomib an NFkB inhibitor is an active agent for the treatment of myeloma MM . We have reported a promising complete remission CR rate for newly diagnosed myeloma patients treated by a staged approach in which chemosensitive patients underwent autologous haematopoietic stem cell transplantation auto-HSCT while less chemosensitive patients received salvage therapy with bortezomib thalidomide dexamethasone prior to auto-HSCT. Methods Herein with an additional 13 months of follow-up we reported the updated survivals and examined potential prognostic factors impacting event-free EFS and overall survival OS . Results With a median follow-up of 30 months the projected OS was 73 and EFS was . Age gender clinical stage and DAPK methylation could not account for the differential chemosensitivity. Advanced ISS stage and DAPK methylation adversely impacted OS whereas oligoclonal reconstitution predicted superior EFS. Conclusions Our staged approach illustrated an economical use of expensive targeted agents while preserving a good CR rate and OS. The comparable survivals of chemosensitive and less chemosensitive patients suggested the staged approach might have abolished the adverse prognostic impact of suboptimal chemosensitivity. Finally the adverse impact of DAPK methylation and favorable impact of oligoclonal reconstitution in myeloma warrants further study. Background Bortezomib an NFkB inhibitor is an active agent for the treatment of myeloma MM . After the demonstration of its efficacy as salvage therapy in chemo-resistant or refractory myeloma patients with a CR rate of 9 1 2 . a high CR rate has also been .